Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

BPC-157 vs TB-500

Peptide Schedule Research TeamReviewed Oct 13, 202613 Citations

vs

BPC-157 and TB-500 are healing peptides that community protocols often pair after an injury. Nearly all of their evidence comes from animal studies, and FDA has proposed keeping both off its compounding list. One 2026 rat study tested them side by side on the same tendon injury.

BPC-157
Healing & Recovery15.2 min IV in rats, 5.3 min in dogs; under 30 min after IM; no human data

A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were preclinical studies. One was clinical. That ratio says a lot about where the science stands right now. The review's orthopaedic search ran through June 3, 2024, and kept studies of mechanism, musculoskeletal outcomes, metabolism and safety. FDA's July 2026 briefing searched every use and counted five small human studies, two known only from meeting abstracts. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. In animal and cell studies, it promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendon cells. One property separates it from most peptides: it stays stable in human gastric juice (PMID 38675421). In rats, oral dosing works for gut injuries; no human study has measured how much of an oral dose is absorbed. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. Its nominators withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.

View full guide →
TB-500
Healing & Recovery~5 hours (estimated, never measured in humans)

Seven amino acids. That is all TB-500 is. Acetylated leucine-lysine-lysine-threonine-glutamate-threonine-glutamine, pulled from positions 17 through 23 of the 43-amino-acid thymosin beta-4 protein. CAS number 885340-08-9, molecular weight 889.0 Da. The mechanism is well characterized in animals. TB-500 binds monomeric G-actin, sequestering free actin subunits and remodeling the cytoskeleton so that endothelial and immune cells migrate faster to damaged tissue. It upregulates VEGF 2.5 to 3.8-fold. Malinda and colleagues confirmed that thymosin beta-4 increased reepithelialization by 42% at day 4 and 61% at day 7 versus controls in rat full-thickness skin wounds (PMID 10469335). It also suppresses myofibroblast differentiation, which reduces scar formation. What makes TB-500 unusual is systemic distribution. You don't need to inject near the injury. Subcutaneous injection in the abdomen reaches a torn rotator cuff the same way it reaches a strained hamstring. Community users have validated this property thousands of times over. No published study has given the TB-500 fragment to people. FDA's briefing for the July 2026 compounding advisory committee meeting found no clinical studies or human exposure data for it by any route. A 2024 metabolite study by Rahaman and colleagues added a wrinkle: the parent compound showed no wound-healing activity in vitro. The metabolite Ac-LKKTE was the active species. That finding has not changed community dosing practices, but it raises questions about mechanism attribution. Community confidence (4.1/5 sentiment, 500+ r/Peptides threads) sits well ahead of the formal evidence base. TB-500 was on the FDA Category 2 list from 2024 until its nominators withdrew it; FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed it on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. All current supply is unregulated gray-market product.

View full guide →

At a Glance

BPC-157 moleculeBPC-157TB-500 moleculeTB-500
CategoryHealing & RecoveryHealing & Recovery
Safety GradeCC
Half-Life15.2 min IV in rats, 5.3 min in dogs; under 30 min after IM; no human data~5 hours (estimated, never measured in humans)
RouteSubcutaneous (near injury) or OralSubcutaneous or Intramuscular
Vial Sizes5 mg, 10 mg2 mg, 5 mg, 10 mg
Beginner Dose250 mcg 2x Daily2 mg 2x/week
Moderate Dose500 mcg Daily2.5 mg 2x/week
Aggressive Dose500 mcg 2x Daily5 mg 2x/week
Dosing SourceCommunityCommunity
Side EffectsFDA's 2026 review counted five small human studies, about 80 people in all; the three published pilots cover about 30 of them. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much. At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs. Anxiety and panic attacks are the most commonly reported serious community side effects. In rats, BPC-157 interacts with dopamine and adrenergic systems (Sikiric and colleagues, PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385). Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect. Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week. Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses. Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing. Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 companies; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination. Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber.No published study has given TB-500 itself to people, and FDA's July 2026 briefing found no human exposure data for it by any route. Two published phase 1 trials gave the full 43-amino-acid thymosin beta-4 intravenously instead. Ruff 2010 enrolled 40 healthy volunteers (PMID 20536472); a 2021 Chinese study enrolled 54 single-dose and 30 multiple-dose volunteers (PMID 34346165). Safety data for the fragment comes almost entirely from community self-reports. Injection site reactions are the most frequently reported problem. Redness, swelling, and tenderness at the injection site appear in a large percentage of users. Rotating between abdomen and thigh reduces local accumulation. Blistering, progressive swelling, or spreading warmth beyond the injection site is abnormal and requires stopping immediately. Fatigue and lethargy during the loading phase (weeks 1 to 2) rank second. Community reports describe this as the most common early side effect at doses of 4 to 5 mg per week. It usually resolves by week 3 without dose adjustment. If fatigue is debilitating, stepping down to 2 mg twice weekly is the standard community recommendation. Headache during loading is common and typically follows the same resolution pattern as fatigue. Nausea is less frequent. Rare but serious reactions include fever above 100.4 degrees F, injection site blistering, skin rash, hives, and muscle aches. Any of these require stopping the protocol and seeking medical evaluation. The unresolved long-term concern is oncogenic risk. TB-500 is pro-angiogenic. It promotes new blood vessel formation. In the presence of occult tumor tissue, this mechanism could theoretically support vascularization and tumor growth. Active cancer or personal cancer history is an absolute contraindication at any dose. Baseline age-appropriate cancer screening (PSA, mammogram, colonoscopy as applicable) is recommended before starting, particularly for anyone over 40. TB-500 is WADA prohibited (S2: Growth Factors) in and out of competition. A 4-year ban was issued in 2024 for documented use. DoD personnel face the same restriction. Pregnancy and breastfeeding: no safety data exists. Do not use.

Key Differences

  • BPC-157 is a 15-amino acid peptide, a partial sequence of a protein isolated from human gastric juice [2]. TB-500 is a 7-amino acid fragment of thymosin beta-4 with an acetyl group on its first amino acid (Ac-LKKTETQ, per FDA's TB-500 briefing).

  • Human data are thin for BPC-157 and absent for TB-500. FDA's 2026 review found five small human studies of BPC-157, with 2 to about 26 people each and about 80 in all. Two of the five exist only as meeting abstracts; the three published pilots cover about 30 people. FDA called the studies short and small, with doses likely exploratory (FDA BPC-157 briefing). For TB-500, FDA found no clinical studies and no human exposure data (FDA TB-500 briefing).

  • No published study has given TB-500 to people. Its human data come from the parent protein. Two phase 1 trials gave intravenous full-length thymosin beta-4 to healthy volunteers. One dosed 40 people at 42 to 1,260 mg [6]. The other gave a recombinant form to 54 people once and 30 daily [7].

  • In animal and cell studies, BPC-157 acts at the injury. It sped the outgrowth and migration of rat tendon fibroblasts [2]. In rats with hind limb ischemia, it sped blood flow recovery and raised VEGFR2, a receptor that drives angiogenesis [3].

  • TB-500's healing case rests mostly on its parent protein. In rat skin wounds, full-length thymosin beta-4 raised re-epithelialization by 42% over saline at day 4. The gain reached up to 61% by day 7 [4]. FDA's May 2026 review said nonclinical evidence was lacking for TB-500 itself to promote wound healing (FDA TB-500 briefing).

  • One study has tested them side by side, in 32 rats with repaired Achilles tendons. The rats got 10 mcg/kg a day of BPC-157 or 60 mcg/kg a day of TB-500 by intraperitoneal injection, a six-fold dose gap. After four weeks, TB-500 significantly raised the tendon's maximum load to failure. BPC-157 raised it too, but not significantly [5]. Tissue scores improved most clearly with TB-500, the combination did no better than either alone, and the authors called the study exploratory.

  • Half-lives are short and poorly measured. BPC-157's elimination half-life was 5 to 15 minutes after an IV dose and under 30 minutes after IM dosing in rats and dogs [1]. FDA found no human pharmacokinetic study of TB-500 (FDA TB-500 briefing), so the 5-hour figure in the table is an estimate. The daily and twice-weekly schedules come from community practice.

  • No trial has set a human dose for either peptide. FDA called the BPC-157 study doses likely exploratory and found no TB-500 human data (FDA briefings). Community tiers run BPC-157 at 250 to 500 mcg once or twice a day, often injected near the injury, for 4 to 6 weeks. TB-500 tiers run 2 to 5 mg twice a week, injected at any site, on the view that it circulates.

  • Side effect data are thin. FDA saw no serious adverse events reported in the BPC-157 studies, but safety monitoring in most of them was unclear (FDA BPC-157 briefing). Community reports flag anxiety, mostly above 500 mcg a day, plus palpitations and mood changes with BPC-157. For TB-500, FDA says the risks in humans are unknown.

  • Both raise angiogenesis in animal work, BPC-157 in rats [3] and full-length thymosin beta-4 in rat wounds [4]. Both profiles list active cancer as a contraindication for that reason, and pregnancy for lack of data.

  • Neither is FDA-approved, and FDA's 2026 review found no approved BPC-157 product in any country (FDA BPC-157 briefing). Both sat in FDA's compounding category 2 until their nominators withdrew them. FDA's list, current as of April 22, 2026, shows both as withdrawn (FDA category 2 page).

  • FDA's 2026 briefings proposed not adding either to the 503A bulks list, and its advisory committee discussed both on July 23, 2026. FDA calls committee recommendations non-binding and has posted no minutes, and 21 CFR 216.23 lists neither. WADA prohibits both at all times, BPC-157 under S0 and TB-500 under S2 (WADA 2026 list).

When to Choose BPC-157

  • One injury site, such as a tendon or ligament (community practice injects near it)

  • Gut symptoms are the target (its parent protein came from gastric juice; oral use is a community practice)

  • Some human data matter to you (five small studies, per FDA's 2026 review)

  • A short course for one area after surgery (community reports)

When to Choose TB-500

  • Several sore areas at once (community reports favor its whole-body reach)

  • Two injections a week suit you better than daily ones (community dosing)

  • Injecting near the injury isn't practical (community practice injects TB-500 anywhere)

  • The rat tendon result matters most to you (TB-500 raised load to failure in rats)[5]

Verdict

Neither has the human evidence to name a winner. In the only head-to-head study, in 32 rats, TB-500 made repaired Achilles tendons significantly stronger at four weeks. BPC-157's gain fell short of significance [5]. BPC-157 has five small human studies; TB-500 has no published one. Community reports favor BPC-157 for a single injury or the gut and TB-500 for several sore areas, and many people run both.

Research peptides with both sides of the evidence.

Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.

Can You Stack BPC-157 + TB-500?

Yes, commonly stacked

BPC-157 + TB-500 is the most common injury recovery stack in community reports, often called the Wolverine Stack. Community protocols inject BPC-157 near the injury and TB-500 anywhere, on the view that the two cover local and whole-body repair. The one controlled test of the pair was in rats, and the combination did no better than either peptide alone [5]. No human trial has tested the pair; a ClinicalTrials.gov search on October 15, 2026, found none registered.

Dosage Calculators

Or use the universal Peptide Calculator for any peptide.

Related Comparisons

Related Guides & Stacks

Explore all Healing & Recovery peptides

Peptide Schedule Research TeamReviewed Oct 13, 202613 Citations

References

  1. [1]Pharmacokinetics of BPC 157 in rats and dogs (He et al., Front Pharmacol 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]BPC 157 and tendon healing: tendon outgrowth, cell survival and fibroblast migration, in rat tendon cells (Chang et al., J Appl Physiol 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Pro-angiogenic BPC 157 and VEGFR2 activation, in rats and endothelial cells (Hsieh et al., J Mol Med 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Thymosin beta4 accelerates wound healing in rats (Malinda et al., J Invest Dermatol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]BPC-157, TB-500 and the two combined on Achilles tendon repair in 32 rats (Biçer et al., Jt Dis Relat Surg 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
  6. [6]Intravenous full-length thymosin beta4 in 40 healthy volunteers, single and multiple doses (Ruff et al., Ann N Y Acad Sci 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
  7. [7]Recombinant human thymosin beta4, first-in-human phase 1 in healthy volunteers (Wang et al., J Cell Mol Med 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed

Frequently Asked Questions

Neither has human data strong enough to say. In the only side-by-side study, in 32 rats with repaired Achilles tendons, TB-500 significantly raised the load the tendon could bear at four weeks. BPC-157's gain did not reach significance (PMID 42542926). BPC-157 has five small human studies, and TB-500 has no published one. Community reports favor BPC-157 for one injury or gut issues and TB-500 for several areas at once.

Community protocols often do, as the Wolverine Stack, with BPC-157 near the injury and TB-500 anywhere. No human trial has tested the pair. In rats with repaired Achilles tendons, the combination did no better than either peptide alone (PMID 42542926). Neither peptide is FDA-approved, and WADA prohibits both for tested athletes.

BPC-157's elimination half-life was 5 to 15 minutes after an IV dose and under 30 minutes after IM dosing in rats and dogs (PMID 36588717); that figure comes from animals. FDA's 2026 review found no human pharmacokinetic study of TB-500, so the 5 hours often quoted is an estimate. The community schedules, daily for BPC-157 and twice weekly for TB-500, do not rest on measured human half-lives.

Daily, in community protocols. Community tiers are 250 mcg twice a day, 500 mcg once a day or 500 mcg twice a day, often for 4 to 6 weeks. TB-500 is the twice-weekly one, at 2 to 5 mg per injection. Neither schedule comes from a trial. FDA called the doses in the small BPC-157 studies likely exploratory.

Not in any published study. FDA's 2026 review found no clinical studies or human exposure data for TB-500. The phase 1 trials people cite gave full-length thymosin beta-4 by IV (PMID 20536472 and PMID 34346165).
13 references